tislelizumab
novartis,beigene
['truce-02', 'bladder', 'tislelizumab', 'urothelial']
truce-02: an open label, single-arm, phase ii study of tislelizumab combined with nab-paclitaxel for high-risk non-muscle-invasive urothelial bladder carcinoma #asco22 
Medical oncologist. Clinical researcher focused in GU tumors. Director Institute of Oncology. Associate Professor UCM. Hospital Clinico San Carlos Madrid, Spain